Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tufts CSDD Names Ken Getz New Deputy Director | Contract Pharma
Breaking News, Promotions & Moves

Tufts CSDD Names Ken Getz New Deputy Director

Mr. Getz also promoted to the rank of Research Professor by Tufts University

Tufts Center for the Study of Drug Development (CSDD) has announced that Ken Getz, who previously served as the Center’s Director of Sponsored Research, has been promoted to the rank Research Professor by Tufts University, and, as of October 1, 2019, has been appointed to the new role of Deputy Director at Tufts CSDD.
 


Tufts CSDD’s new deputy director Ken Getz.
Mr. Getz joined the Tufts CSDD in 2005 and has achieved international recognition for his cutting-edge research in the areas of R&D management, the investigative site landscape, outsourcing practices, and protocol optimization.
 
“Ken’s pioneering studies on clinical trial operations and R&D efficiency, have had a profound and lasting impact on the way new drug candidates are investigated and developed in the U.S. and abroad,” said Tufts CSDD Director Ken Kaitin. “Moreover, Ken’s sizeable body of work on global outsourcing practices, patient recruitment and retention, and investigative site management has contributed substantially to our understanding of these critical aspects of drug development and how they are evolving. I could not be more thrilled to work alongside Ken in his new role as CSDD Deputy Director.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters